Abstracts tagged "Wegener’s granulomatosis"

Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…
Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting
Cardiac Involvement In Granulomatosis With Polyangiitis
Lucy McGeoch¹, Simon Carette², David Cuthberston³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L Koening⁶, Carol A. Langford⁷, Paul A. Monach⁸, Larry W. Moreland⁹, Philip Seo¹⁰, Ulrich Specks¹¹, Steven R. Ytterberg¹², Carol McAlear¹³, Peter A Merkel¹⁴, Christian Pagnoux² and The Vcrc¹⁵, ¹Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Biostatistics, University of South Florida, Tampa, FL, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, Boston University, Boston, MA, ⁹Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹¹Mayo Clinic, Rochester, MN, ¹²Rheumatology Division, Mayo Clinic, Rochester, MN, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ¹⁵University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…
Abstract Number: 743 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab For Otolaryngologic (ENT) Manifestations Of Granulomatosis With Polyangiitis (GPA, Wegener’s granulomatosis)
Lindsay Lally¹, Robert Lebovics², Wei-Ti Huang³ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Otolaryngology, St. Luke's-Roosevelt Hospital Center, New York, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY
Background/Purpose: ENT involvement is the most prevalent manifestation of GPA. Rituximab (RTX) is a proven effective remission induction therapy for severe GPA with vasculitic manifestations. …
Abstract Number: 1527 • 2012 ACR/ARHP Annual Meeting
Patient Global Assessments for Disease Activity Are Predictive of Future Flare in Granulomatosis with Polyangiitis (Wegener’s)
Gunnar Tomasson¹, John C. Davis Jr.², Gary S. Hoffman³, W. Joseph McCune⁴, Ulrich Specks⁵, Robert F. Spiera⁶, E. William St. Clair⁷, John H. Stone⁸ and Peter A. Merkel⁹, ¹Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland, ²Genentech, Inc, South San Francisco, CA, ³Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁴Int Med/ Rheum, University of Michigan, Ann Arbor, MI, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Medicine, Duke University Medical Center, Durham, NC, ⁸Rheumatology, Massachusetts General Hospital, Boston, MA, ⁹University of Pennsylvania, Philadelphia, PA
Background/Purpose: In granulomatosis with polyangiitis GPA), disease activity is assessed by physician-based measures. In some other rheumatic diseases, such as rheumatoid arthritis (RA) and ankylosing…
Abstract Number: 1530 • 2012 ACR/ARHP Annual Meeting
Plasma Cell Analysis As a Biomarker for Disease Activity in Patients with Granulomatosis with Polyangiitis
Bimba F. Hoyer¹, Adriano Taddeo², Maika Rothkegel², Gerd Burmester³, Andreas H. Radbruch² and Falk Hiepe⁴, ¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ²Deutsches Rheumaforschungszentrum, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Med. Klinik m. Sp. Rheumatologie und klin. Immunologie, Charité University Hospital Berlin, Berlin, Germany
Background/Purpose: B cells are thought to play an important role in granulomatosis with polyangiitis (GPA) due to the presence of autoantibodies reacting with specific neutrophil…
Abstract Number: 1534 • 2012 ACR/ARHP Annual Meeting
IgG4 Plasma Cell Infiltration in Granulomatosis with Polyangiitis (formerly Wegener’s) Lung Biopsies
Mollie Carruthers¹, Shweta Shinagare², Arezou Khosroshahi¹, Vikram Deshpande² and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) and IgG4-related disease (IgG4-RD) are both immune-mediated conditions that can involve multiple organ systems. In GPA, IgG4-positive plasma cell infiltration…
Abstract Number: 2596 • 2012 ACR/ARHP Annual Meeting
Rituximab Treatment for Antineutrophil Cytoplasmic Antibody – Associated Vasculitis in Children
Katharine F. Moore¹, Leonard L. Dragone², Jennifer B. Soep³ and J. Roger Hollister⁴, ¹Pediatric Rheumatology, Seattle Children's Hospital / University of Washington, Seattle, WA, ²Dept of Pediatrics, National Jewish Health, Denver, CO, ³Pediatric Rheumatology, Children's Hospital Colorado, Aurora, CO, ⁴Dept of Pediatrics, Children's Hospital Colorado, Aurora, CO
Background/Purpose: The purpose of this study was to report the experience of a tertiary-care children’s hospital using rituximab in the treatment of pediatric antineutrophil cytoplasmic…
Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting
A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Carla Maldini¹, Matthieu Resche-Rigon², David Jayne³, Kerstin Westman⁴ and Alfred Mahr¹, ¹Internal Medicine, Hospital Saint-Louis, Paris, France, ²Biostatistics, Hopital Saint-Louis, Paris, France, ³Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁴Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…
Abstract Number: 2393 • 2012 ACR/ARHP Annual Meeting
High Mobility Group Box 1 Levels Are Not Associated with Subclinical Carotid Atherosclerosis in Patients with Granulomatosis with Polyangiitis but Are Reduced by Glucocorticoids and Statins
Alexandre Wagner S. de Souza¹, Karina de Leeuw², Johanna Westra², Andries J. Smit³, Anne Marijn van der Graaf², Hans L. A. Nienhuis¹, Johan Bijzet², Pieter C. Limburg⁴, Coen A. Stegeman⁵, Marc Bijl⁶ and Cees G.M. Kallenberg², ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Vascular Diseases, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Department of Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ⁵Nephrology, University Medical Center Groningen, Groningen, Netherlands, ⁶Rheumatology and Clinical Immunology, Martini Hospital, Groningen, Netherlands
Background/Purpose: High mobility group box 1 (HMGB1) is a non-histone DNA binding protein that is passively released by dying cells or actively secreted by immunocompetent…
Abstract Number: 2397 • 2012 ACR/ARHP Annual Meeting
Urinary Biomarkers in Vasculitis Associated with Anti-Neutrophil Cytoplasmic Antibodies
Jason G. Lieberthal¹, David Cuthbertson², Simon Carette³, Gary S. Hoffman⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Kathleen Maksimowicz-McKinnon⁸, Philip Seo⁹, Ulrich Specks¹⁰, Steven R. Ytterberg¹¹, Peter A. Merkel¹² and Paul A. Monach¹³, ¹Medicine, Boston University School of Medicine, Boston, MA, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Div of Rheum/E1-422, UHN/MSH, Toronto, ON, Canada, ⁴Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁵Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Internal Medicine, Salt Lake City Veterans Administration, Salt Lake City, UT, ⁷Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁸Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Rheumatology Division, Mayo Clinic, Rochester, MN, ¹²University of Pennsylvania, Philadelphia, PA, ¹³Rheumatology, Boston University, Boston, MA
Background/Purpose: Glomerulonephritis is common in ANCA-associated vasculitis (AAV), but non-invasive tools for early detection of renal involvement suffer from low sensitivity (red blood cell…
Abstract Number: 1653 • 2012 ACR/ARHP Annual Meeting
Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy
Jason Springer¹, Benjamin Nutter², Carol A. Langford³, Gary S. Hoffman⁴ and Alexandra Villa-Forte⁵, ¹Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ³Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Disease remission can be successfully achieved in the majority of patients (pts) with Granulomatosis with polyangiitis (Wegener’s) (GPA). After remission (rem) is achieved continued…
Abstract Number: 1655 • 2012 ACR/ARHP Annual Meeting
An Open-Label Trial of Abatacept in Mild Relapsing Granulomatosis with Polyangiitis (Wegener’s)
Carol A. Langford¹, David Cuthbertson², Gary S. Hoffman³, Jeffrey Krischer⁴, Carol McAlear⁵, Paul A. Monach⁶, Philip Seo⁷, Ulrich Specks⁸, Steven R. Ytterberg⁹, Peter A. Merkel⁵ and for the Vasculitis Clinical Research Consortium⁵, ¹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ²Department of Biostatistics, University of South Florida, Tampa, FL, ³Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁴University of South Florida, Tampa, FL, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁸Mayo Clinic, Rochester, MN, ⁹Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Granulomatosis with polyangiitis (Wegener's, GPA) is a primary systemic vasculitis that carries a high predilection for relapse. An area of unmet need has been…
Abstract Number: 1537 • 2012 ACR/ARHP Annual Meeting
Pathogenesis of Atherosclerosis in Granulomatosis Polyangiitis
Rula Hajj-Ali¹, Roy L. Silverstein², Gary S. Hoffman³ and Carol A. Langford⁴, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatic & Immunologic Dis, Cleveland Clinic Found A50, Cleveland, OH, ⁴Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH
Background/Purpose: Previous studies from our group suggested that the inflammatory events that occur during relapses in patients with Granulomatosis with Polyangiitis (GPA, Wegener’s) may have…
Abstract Number: 1540 • 2012 ACR/ARHP Annual Meeting
Practice Patterns in the Treatment of ANCA-Associated Vasculitis: Exploring Differences Among Subspecialties At a Single Academic Medical Center
Lindsy J. Forbess¹, Kenneth W. Griffin² and Robert F. Spiera³, ¹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²Public Health, Weill Cornell Medical College, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Randomized controlled trial evidence helps guide physician treatment choices for ANCA-Associated Vasculitis (AAV). Data for remission maintenance therapy following rituximab (RTX) in generalized disease,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].